Search Result

Results for "

NSG

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (5) Caspase (1) CD3 (2) CD6 (1) CDK (1) Dihydroorotate Dehydrogenase (1) Histone Acetyltransferase (1) JAK (1) LAG-3 (1) MicroRNA (1) PARP (1) PD-1/PD-L1 (1) PDI (2) PROTACs (2) Small Interfering RNA (siRNA) (2)
By Research Areas:	Cancer (10) Infection (1) Inflammation/Immunology (4) Metabolic Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99199

Foralumab NI-0401	CD3	Inflammation/Immunology
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .

HY-RS09593

NSG1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NSG1 Human Pre-designed siRNA Set A contains three designed siRNAs for NSG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSG1 Human Pre-designed siRNA Set A NSG1 Human Pre-designed siRNA Set A

HY-RS09594

NSG2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NSG2 Human Pre-designed siRNA Set A contains three designed siRNAs for NSG2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSG2 Human Pre-designed siRNA Set A NSG2 Human Pre-designed siRNA Set A

HY-P99354

Bavunalimab Anti-Human CTLA4xLAG3	LAG-3	Inflammation/Immunology Cancer
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .

HY-115581

Thymidine 3',5'-disphosphate Deoxythymidine 3′,5′-diphosphate; pdTp	Apoptosis	Cancer
Thymidine 3',5'-disphosphate (Deoxythymidine 3′,5′-diphosphate; pdTp) is a selective small molecule inhibitor of staphylococcal nuclease and tudor domain containing 1 (SND1, the miRNA regulatory complex RISC subunit) and inhibits SND1 activity. Thymidine 3',5'-disphosphate exhibits anti-tumor efficacy in vivo .

HY-115581A

Thymidine 3',5'-diphosphate tetrasodium Deoxythymidine 3′,5′-diphosphate tetrasodium; pdTp tetrasodium	Apoptosis MicroRNA	Cancer
Thymidine 3',5'-diphosphate (Deoxythymidine 3′,5′-diphosphate) tetrasodium is a selective inhibitor of staphylococcal nuclease and tudor domain containing 1 (SND1, the MicroRNA regulatory complex RISC subunit) and [3,5- ²H₂] tyrosyl nuclease. Thymidine 3',5'-diphosphate tetrasodium has anti-tumor activity and can also be used as a catalyst in biochemical reactions .

HY-162343

PD-1/PD-L1-IN-41

PD-1/PD-L1 Inflammation/Immunology Cancer

PD-1/ PD-L1-in-41 (Compound 5c) is a PD-L1 and PD-1 inhibitor with IC₅₀ value of 10.2 nM .

PD-1/PD-L1-IN-41	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a PD-L1 and PD-1 inhibitor with IC₅₀ value of 10.2 nM .

HY-151902

SJ988497	PROTACs JAK	Cancer
SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL) .

HY-145765

JQAD1	PROTACs Histone Acetyltransferase Apoptosis Caspase PARP	Cancer
JQAD1 is a CRBN-dependent PROTAC that selectively targets EP300 for degradation. JQAD1 suppresses EP300 expression and the H3K27ac modification. JQAD1 induces apoptosis. JQAD1 can be used in research of cancer .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-149031

DHODH-IN-22	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-22 is a potent, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 0.3 nM. DHODH-IN-22 can be used for researching acute myelogenous leukemia (AML) .

HY-122895A

(E/Z)-E64FC26	Apoptosis PDI	Cancer
(E/Z)-E64FC26 is a mixture complex of E-E64FC26 and Z-E64FC26. E64FC26 (E-E64FC26) is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC₅₀s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6. E64FC26 shows anti-myeloma activity .

HY-122895

E64FC26 1 Publications Verification	Apoptosis PDI	Cancer
E64FC26 is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC₅₀s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6, respectively. E64FC26 shows anti-myeloma activity .

HY-143889

Senexin C	CDK	Cancer
Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability .

HY-P99252

Itolizumab Anti-Human CD6 Recombinant Antibody	CD6	Infection Inflammation/Immunology
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .

Foralumab NI-0401	CD3	Inflammation/Immunology
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

Itolizumab Anti-Human CD6 Recombinant Antibody	CD6	Infection Inflammation/Immunology
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .

Bavunalimab Anti-Human CTLA4xLAG3	LAG-3	Inflammation/Immunology Cancer
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.